Tuesday, November 22, 2011

• S*BIO's Novel JAK2 Inhibitor Pacritinib (SB1518) and Histone Deacetylase Inhibitor Pracinostat (SB939) Demonstrate Promising Activity in Phase 2 Studies for Patients with Myelofibrosis (MF)

  SINGAPORE, Nov. 22, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced that data from Phase 2 studies for its JAK2 inhibitor pacritinib (SB1518) and histone deacetylase inhibitor pracinostat (SB939) demonstrate promising activity in patients with myelofibrosis (MF). Results will be presented at the 53rd ... read more